Navigation Links
VCU Massey Cancer Center spearheads novel clinical study for lymphoma patients
Date:9/2/2008

The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma.

The study is based on research from VCU Massey Cancer Center as well as other centers suggesting that combining two novel, recently approved drugs that have shown effectiveness in certain blood cancers may be active in patients with diffuse large B-cell lymphoma, or mantle cell lymphoma. The study is intended for patients whose disease has progressed following treatment with other regimens.

Other NCI centers participating in this novel lymphoma study through the NCI's Southeast Phase II Consortium include H. Lee Moffitt Cancer Center and Research Institute (Tampa, Fla.), which is the coordinating center; the University of North Carolina Lineberger Comprehensive Cancer Center (Chapel Hill, N.C.); and the Vanderbilt-Ingram Cancer Center (Nashville, Tenn.). Also planning to participate are Montefiore-Einstein Cancer Center (New York); and New York Presbyterian Hospital / Weill Cornell Medical College, both of which are in the NCI-sponsored New York Phase II Consortium.

The investigators hope to learn whether these types of lymphoma respond to treatment with the combination of bortezomib, marketed as Velcade, and vorinostat, marketed as Zolinza. They also intend to learn about the side effects of this drug regimen and whether certain features of these lymphomas might predict for response to this regimen.

Steven Grant, M.D., principal investigator of the study and associate director for translational research at VCU Massey Cancer Center, is among a number of researchers worldwide who have reported synergistic interactions between proteasome inhibitors such as bortezomib and histone deacetylase inhibitors such as vorinostat in leukemia and other hematologic malignancies. Other cancer centers are currently exploring this drug combination in
'/>"/>

Contact: Andrea Butler
albutler@vcu.edu
804-628-2111
Virginia Commonwealth University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. VCU Massey Cancer Center to partner with Israeli biotech firm
2. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
3. Survival differences by race most apparent in advanced stages of breast cancer
4. MRI finds breast cancer before it becomes dangerous
5. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
6. Pathway links inflammation, angiogenesis and breast cancer
7. Radiologists encouraged to look beyond cancer for clinically unseen diseases
8. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
9. Immune deficiency linked to a type of eye cancer
10. Drop in breast cancer incidence linked to hormone use, not mammograms
11. Breast cancer prevention practices vary across Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... Mile High Connects today releases “First and Last ... funding for sidewalks, bike paths, and other vital supports severely limit access to public ... billions of dollars to expand public transit, there’s very little support for safe and ...
(Date:9/4/2015)... ... September 04, 2015 , ... After wearing the same uniforms ... of new apparel. In an effort to assist the team, the Jones Agency, a ... charity drive to raise funds for the new uniforms. , As is so often ...
(Date:9/4/2015)... ... September 04, 2015 , ... San Francisco ... at CitiDent. CEREC is a newer method for creating restorations through innovative imaging ... by eliminating the need for multiple appointments, CEREC produces restorations with total precision ...
(Date:9/4/2015)... ... September 04, 2015 , ... The USC Eye Institute is proud ... nationwide by Doximity. Faculty, residents and staff are honored to have contributed to ... quality of our ophthalmology residency program. Our faculty places a high priority on our ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... Residence in South Glastonbury, Connecticut, has been selected for the Residential Award of ... energy efficiency and resiliency measures. Chosen from a highly competitive field of submissions, ...
Breaking Medicine News(10 mins):Health News:Missed Connections in Metro Denver Transit 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2
... , ENGLEWOOD, Colo., Aug. 10 Baxa, ... and administration of fluid medications, announces the launch of a ... and medication safety practices. The Culture of Safety Page, ... share experiences, insights and ideas for improving their profession and ...
... Aug. 10 /PRNewswire-Asia/ -- China Medicine Corporation,(OTC Bulletin ... leading,developer and distributor of prescription and over the ... supplements, and,medical devices and medical formulations, today announced ... a.m. Eastern Time on Thursday, August 13, 2009, ...
... , SAN FRANCISCO, Aug. 10 ... Mark Gastineau to senior vice president and chief executive of ... Unit (ISGBU). Gastineau joined Blue Shield in 2006 as ... underwriting and compliance areas in developing strategies to increase membership ...
... ... and school administrators will help U.S. schools meet growing needs of students with autism ... ... Society announced the publication of professional competencies for teaching students with autism spectrum disorders ...
... , , NEW YORK, Aug. 10 ... letter of intent to form ZiRx Therapeutics, Ltd., a joint venture that ... cell proteins with drugs that potentially block or stop the spread of ... to broad spectrum antiviral drugs as well as drugs that are less ...
... YORK, Aug. 10 In an unprecedented meeting at the UN, ... and currently an opposition leader and human rights protagonist for Iran, ... violations of human rights by the regime in Iran. , ... Secretary General for his June 22 statement of urgent concern over ...
Cached Medicine News:Health News:Baxa Corporation Launches 'Culture of Safety' Facebook Page 2Health News:Baxa Corporation Launches 'Culture of Safety' Facebook Page 3Health News:China Medicine Announces Conference Call to Discuss Second Quarter 2009 Results 2Health News:Mark Gastineau Named Senior Vice President of Individual, Small Group, and Government Business Unit at Blue Shield of California 2Health News:New National Professional Competencies for Teachers of Autism Released by Leaders in the Field 2Health News:New National Professional Competencies for Teachers of Autism Released by Leaders in the Field 3Health News:Rx for Africa, Inc. and Zirus, Inc. Create Joint Venture, ZiRx Therapeutics, Ltd. 2Health News:Rx for Africa, Inc. and Zirus, Inc. Create Joint Venture, ZiRx Therapeutics, Ltd. 3Health News:Former UN Human Rights Rapporteur Offers 7 Points of Action on Iran to the UN Secretary General 2
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
Malaria (P. fal.) Ag Rapid Test...
Malaria P.f. Rapid Test Device...
Core Malaria Pv/Pf is a self performing, qualitative, sandwich immunoassay for the detection and differentiation of vivax malaria and falciparum malaria in whole blood samples....
Ultraview 1700 Central Monitor...
Medicine Products: